Administrative Core
行政核心
基本信息
- 批准号:10684228
- 负责人:
- 金额:$ 41.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAdministratorAgreementAreaBiological AssayBiological MarkersBiopsyClinicalCollaborationsCommon Data ElementCommunitiesDataData AnalysesData Coordinating CenterDevelopmentDiagnostic testsDiseaseERG geneEarly Detection Research NetworkEarly DiagnosisEnsureFundingFutureGene FusionGoalsGuidelinesHealthIndustryInformed ConsentInstitutionInstitutional Review BoardsInvestigationKnowledgeLaboratoriesLeadershipMalignant NeoplasmsMalignant neoplasm of prostateManuscriptsMethodsMichiganMissionMonitorMutationNetwork InfrastructureOccupational activity of managing financesPSA screeningPathologyPopulations at RiskPrincipal InvestigatorProceduresProgress ReportsProstateProstatic DiseasesRNA SplicingReportingResearchResearch PersonnelResourcesSamplingScreening for Prostate CancerSpecimenStandardizationStructure of base of prostateTMPRSS2 geneTestingTexasTranscriptTranslatingTranslationsTravelUniversitiesUniversity resourcesUntranslated RNAUrineValidationVariantVirginiaVisionWorkantigen testbiobankbiomarker developmentbiomarker validationcancer biomarkerscircular RNAcohortcommercializationcurative treatmentsdata sharingdata submissiondetection testimprovedindustry partnerinsertion/deletion mutationmedical schoolsmeetingsmultidisciplinarynext generationnovelnovel diagnosticsnovel markeroperationpersonalized risk predictionprogramsprotocol developmentscreeningserum PSAshared decision makingspecific biomarkerssuccesstranscriptome sequencingtranscriptomicstranslational goalurinaryvalidation studies
项目摘要
Project Summary/Abstract
This application proposes the formation of the Michigan-Vanderbilt University Medical Center (VUMC) EDRN
Biomarker Characterization Center (BCC). This BCC represents a collaborative, multi-disciplinary team of
academic (University of Michigan (U-M) and VUMC) and industry (LynxDx) partners focused on discovering,
developing, and scaling clinical-grade assays for the early detection of aggressive prostate cancer. Through
previous EDRN efforts, our team characterized multiple important prostate cancer biomarkers, most notably the
TMPRSS2-ETS gene fusions. Through collaboration with an EDRN Clinical Validation Center (CVC; Dr. Sanda
PI), we developed, validated, and clinically implemented MyProstateScore (MPS), an early detection test
incorporating urine quantification of two prostate cancer-specific transcripts—the TMPRSS2:ERG gene fusion
and the long non-coding RNA (lncRNA) PCA3. Introduced in our CLIA laboratory, MPS informs shared decision
making after PSA testing based on individualized risk predictions of aggressive prostate cancer on biopsy. Here,
pairing the cancer-specific components of the MPS test with recent discovery of high-grade cancer-specific
biomarkers, we outline the development, optimization, and clinical validation of the next generation of diagnostic
tests – capable of reliably, selectively detecting potentially lethal cancers that stand to benefit from early curative
treatment. Our Biomarker Developmental Laboratory (BDL) will employ the experimental platform, MPS-SEQ,
for capture RNA-seq analysis of urine samples to detect aggressive prostate cancer transcripts, lncRNAs,
circular RNAs, fusion transcripts, mutations, indels, and splice variants. Our Biomarker Reference Laboratory
(BRL) will in parallel develop a clinical grade urine assay, MPS-50, for the multiplex QPCR analysis of up to 50
amplicons. While the first 50 amplicons of MPS-50 have already been nominated, future improvements of the
assay content and platform will be informed by work carried out in our BDL. To fuel these studies, our BCC has
identified urine biospecimen cohorts collected under rigorous standard operating procedures in compliance with
PRoBE criteria including the Michigan Prostate SPORE, Emory University, the Center for Prostate Disease
Research, University of Texas San Antonio Health, Eastern Virginia Medical School, and VUMC/Meharry
Medical College. The overall Aims of this BCC serve to develop, assess, and optimize MPS-SEQ and MPS-50
for identifying high-grade prostate cancer in diverse at-risk populations. Our BRL will also focus on standardizing
clinically-validated biomarker assays for consistent and reliable use in accordance with CLIA/CAP guidelines at
the U-M Center for Translational Pathology in order to facilitate network consortium studies and at LynxDx in
order to scale, commercialize, and obtain FDA approvals. As recognized by the EDRN, novel biomarkers specific
for aggressive prostate cancer are urgently needed. Importantly, our mission and efforts extend beyond our BCC
and prostate cancer, as we actively participate in the EDRN biomarker community and support continued
collaborative efforts with other BCCs and CVCs to advance the overall EDRN mission.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ARUL M CHINNAIYAN其他文献
ARUL M CHINNAIYAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ARUL M CHINNAIYAN', 18)}}的其他基金
Michigan-VUMC Biomarker Characterization Center
密歇根-VUMC 生物标志物表征中心
- 批准号:
10483357 - 财政年份:2022
- 资助金额:
$ 41.87万 - 项目类别:
Michigan-VUMC Biomarker Characterization Center
密歇根-VUMC 生物标志物表征中心
- 批准号:
10684207 - 财政年份:2022
- 资助金额:
$ 41.87万 - 项目类别:
Exploring Precision Oncology: From Gene Fusions to lncRNAs
探索精准肿瘤学:从基因融合到 lncRNA
- 批准号:
10219190 - 财政年份:2018
- 资助金额:
$ 41.87万 - 项目类别:
Exploring Precision Oncology: From Gene Fusions to lncRNAs
探索精准肿瘤学:从基因融合到 lncRNA
- 批准号:
10462574 - 财政年份:2018
- 资助金额:
$ 41.87万 - 项目类别:
Exploring Precision Oncology: From Gene Fusions to lncRNAs
探索精准肿瘤学:从基因融合到 lncRNA
- 批准号:
10000857 - 财政年份:2018
- 资助金额:
$ 41.87万 - 项目类别:
Exploring Precision Oncology: From Gene Fusions to lncRNAs
探索精准肿瘤学:从基因融合到 lncRNA
- 批准号:
10680474 - 财政年份:2018
- 资助金额:
$ 41.87万 - 项目类别:
相似海外基金
EAGER: Toward a Decentralized Cross-administrator Zone Management System: Policy and Technology
EAGER:走向去中心化的跨管理员区域管理系统:政策和技术
- 批准号:
2331936 - 财政年份:2023
- 资助金额:
$ 41.87万 - 项目类别:
Standard Grant
COLLABORATIVE RESEARCH: Social Influence in Eyewitness Identification Procedures: Do Blind Administrator Behaviors Magnify the Effects of Suspect Bias?
合作研究:目击者识别程序中的社会影响:盲目的管理员行为是否会放大嫌疑人偏见的影响?
- 批准号:
2043230 - 财政年份:2021
- 资助金额:
$ 41.87万 - 项目类别:
Continuing Grant
COLLABORATIVE RESEARCH: Social Influence in Eyewitness Identification Procedures: Do Blind Administrator Behaviors Magnify the Effects of Suspect Bias?
合作研究:目击者识别程序中的社会影响:盲目的管理员行为是否会放大嫌疑人偏见的影响?
- 批准号:
2043334 - 财政年份:2021
- 资助金额:
$ 41.87万 - 项目类别:
Continuing Grant
Making of the base for patient safety management skill of visiting nurse administrator by the web conference system
利用网络会议系统构建出诊护士管理者患者安全管理技能基础
- 批准号:
19K10768 - 财政年份:2019
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of the nursing administrator training program to improve leadership behavior focused on emotional intelligence
制定护理管理人员培训计划,以改善以情商为重点的领导行为
- 批准号:
18K17464 - 财政年份:2018
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Automated Network Management that Dynamically Reflects Administrator Intent
动态反映管理员意图的自动化网络管理
- 批准号:
18K18038 - 财政年份:2018
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Administrator support perceived as useful for professional growth by novice psychiatric home-visit nursing staff
新手精神科家访护理人员认为管理员支持对专业成长有用
- 批准号:
17H07005 - 财政年份:2017
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
The Facts and Problems on Management of Public Museums: Validation of Designated Administrator System
公共博物馆管理的事实与问题:指定管理员制度的验证
- 批准号:
17K01212 - 财政年份:2017
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Study on Transformation of the School Administrator Preparation and Evaluation System in the United States
美国学校管理人员培养与评价体系转型研究
- 批准号:
26780449 - 财政年份:2014
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The Family Court's Supervision of Property Administrator
家庭法院对财产管理人的监督
- 批准号:
26380108 - 财政年份:2014
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)